Last reviewed · How we verify
Enteric Coated Mycophenolate Sodium
Enteric Coated Mycophenolate Sodium, marketed by Bristol-Myers Squibb, is an established immunosuppressive agent with a key composition patent expiring in 2028. The drug's primary strength lies in its well-documented efficacy and safety profile, which has solidified its position in the market. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Enteric Coated Mycophenolate Sodium |
|---|---|
| Also known as | Myfortic |
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (PHASE3)
- ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center (PHASE4)
- Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (PHASE3)
- Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients (PHASE4)
- Long-term Benefit of MPA in Liver Transplantation
- Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enteric Coated Mycophenolate Sodium CI brief — competitive landscape report
- Enteric Coated Mycophenolate Sodium updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI